Source-grounded facts extracted from Moderna, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Moderna, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for year ending December 31, 2026 at the 2026-05-06 meeting.
“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, with the votes cast as follows: Votes For Votes Against Abstain 298,823,277 3,406,479 285,923”
Moderna, Inc. shareholders approved Approval, on a non-binding advisory basis, of the frequency of future non-binding advisory votes to approve the compensation of the Company’s named executive officers at the 2026-05-06 meeting.
“The results of the stockholders’ vote to hold an advisory vote to determine the frequency of future stockholder advisory votes on the compensation paid to the Company’s named executive officers were as follows: 1 year 2 years 3 years Abstain 259,590,666 113,043 618,688 281,418”
Moderna, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2026-05-06 meeting.
“The Company’s stockholders approved, on an advisory basis, the compensation of the named executive officers. The result of the stockholders’ vote with respect to the approval of the compensation of the named executive officers was as follows: Votes For Votes Against Abstain 169,401,841 90,761,924 440,050 There were 41,911,864 broker non-votes on the proposal.”
Moderna, Inc. shareholders approved Election of Class II directors for a three-year term expiring at the 2029 Annual Meeting at the 2026-05-06 meeting.
“By the vote reflected below, the Company’s stockholders elected each of the following individuals to serve as a Class II director for a three-year term expiring at the Company’s 2029 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified, or such director’s earlier death, resignation or removal: Votes For Votes Against Abstain Broker Non-Votes Sandra Horning, M.D. 210,914,932 49,357,015 331,868 41,911,864 Abbas Hussain 256,398,374 4,015,044 190,397 41,911,864”
Moderna, Inc.: Amendment to designate federal district courts as exclusive forum for Securities Act claims (effective 2026-05-06).
“On May 6, 2026 , the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated By-Laws (the “By-Law Amendment”), effective immediately, to designate the federal district courts of the United States as the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, unless the Company consents in writing to the selection of an alternative forum.”
Moderna, Inc. reported first quarter ended March 31, 2026 results: revenue $389 million, net income $(1.3) billion, EPS $(3.40).
“Total revenue for the first quarter of 2026 was $389 million, an increase of $281 million compared to the same period in 2025.”
Moderna, Inc. entered into Settlement Agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH valued at $950 million noncontingent lump sum payment (effective 2026-03-03).
“On March 3, 2026 (the “Effective Date”), Moderna, Inc. (the “Company”) and ModernaTX, Inc. (together with the Company, “Moderna”) and Arbutus Biopharma Corporation (“Arbutus”), Genevant Sciences GmbH (“Genevant” and, together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Moderna and Arbutus/Genevant pending in the U.S. and internationally (the “Litigation”).”
Moderna, Inc. incurred credit facility of $1,500,000,000 credit facility with Ares Capital Corporation at Term SOFR plus an applicable margin of 5.50% per annum or base rate plus an appl maturing November 24, 2030.
“The Credit Agreement provides for a $1,500,000,000 credit facility of which $600,000,000 will be funded as an initial term loan and $900,000,000 will be available as delayed draw term loans.”
Abbas Hussain was appointed as Director at Moderna, Inc..
“On September 28, 2024, the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Abbas Hussain to the Board, effective October 2, 2024.”
David M. Rubenstein was appointed as Director at Moderna, Inc..
“On July 19, 2024, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed David M. Rubenstein to the Board, effective August 5, 2024.”
Stephen Berenson resigned as Director at Moderna, Inc..
“On July 19, 2024, Robert Langer and Stephen Berenson each notified Moderna, Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), including all committees on which he serves, effective August 5, 2024.”
Robert Langer resigned as Director at Moderna, Inc..
“On July 19, 2024, Robert Langer and Stephen Berenson each notified Moderna, Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), including all committees on which he serves, effective August 5, 2024.”
Moderna, Inc.: Amended by-laws to include safeguards and requirements for calling special meetings, contingent on stockholder approval of the special meeting amendment (effective 2024-05-08).
“the Board previously approved a corresponding amendment to the Company’s Second Amended and Restated By-laws (the “By-laws”), subject to stockholder approval of the Special Meeting Amendment, to include safeguards and requirements for calling special meetings”
Moderna, Inc.: Amended certificate of incorporation to provide for exculpation of executive officers as permitted under Delaware law (effective 2024-05-08).
“(ii) a Certificate of Amendment to the Charter to provide for the exculpation of the Company’s executive officers, as permitted under Delaware law”
Moderna, Inc.: Amended certificate of incorporation to provide shareholders holding at least 20% of outstanding shares the right to call a special meeting (effective 2024-05-08).
“the Company’s stockholders approved (i) a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) to provide shareholders holding no less than 20% of the Company’s outstanding shares the right to call a special meeting of stockholders”
Moderna, Inc. shareholders approved Management proposal to approve an amendment to the Amended and Restated Certificate of Incorporation to provide stockholders the right to call a special meeting at the 2024-05-06 meeting.
“Management proposal to approve an amendment to the Amended and Restated Certificate of Incorporation to provide stockholders the right to call a special meeting. The Company’s stockholders approved an amendment to the Charter to provide stockholders the right to call a special meeting, as described in”
Moderna, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for year ending December 31, 2024 at the 2024-05-06 meeting.
“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024, with the votes cast as follows: Votes For Votes Against Abstain 302,267,645 1,386,579 1,087,955”
Moderna, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2024-05-06 meeting.
“The Company’s stockholders approved, on an advisory basis, the compensation of the named executive officers. The result of the stockholders’ vote with respect to the approval of the compensation of the named executive officers was as follows: Votes For Votes Against Abstain 248,175,284 25,923,518 488,279”
Moderna, Inc. shareholders approved Election of Elizabeth Tallett as Class III director at the 2024-05-06 meeting.
“By the vote reflected below, the Company’s stockholders elected each of the following individuals to serve as a Class III director for a three-year term expiring at the Company’s 2027 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified, or such director’s earlier death, resignation or removal: For Against Abstain Broker Non-Votes Robert Langer 220,067,098 54,371,254 148,729 30,155,098 Elizabeth Nabel, M.D. 266,133,109 8,295,214 158,758 30,155,098 Elizabeth Tallett 258,746,566 15,688,110 152,405 30,155,098”
Moderna, Inc. shareholders approved Election of Elizabeth Nabel, M.D. as Class III director at the 2024-05-06 meeting.
“By the vote reflected below, the Company’s stockholders elected each of the following individuals to serve as a Class III director for a three-year term expiring at the Company’s 2027 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified, or such director’s earlier death, resignation or removal: For Against Abstain Broker Non-Votes Robert Langer 220,067,098 54,371,254 148,729 30,155,098 Elizabeth Nabel, M.D. 266,133,109 8,295,214 158,758 30,155,098”
Moderna, Inc. shareholders approved Election of Robert Langer as Class III director at the 2024-05-06 meeting.
“By the vote reflected below, the Company’s stockholders elected each of the following individuals to serve as a Class III director for a three-year term expiring at the Company’s 2027 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified, or such director’s earlier death, resignation or removal: For Against Abstain Broker Non-Votes Robert Langer 220,067,098 54,371,254 148,729 30,155,098”
Moderna, Inc. reported the first quarter ended March 31, 2024 results: revenue $167 million, net income GAAP net loss of $1.2 billion, EPS GAAP diluted EPS of $(3.07). Guidance reaffirmed.
“Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates Reports first quarter revenues of $167 million , GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.